Daily Medical Update

Congestive Heart Failure (HFpEF vs HFrEF management)

Saturday, February 7, 2026

🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the last 12 months.

1. Finerenone and Potassium/Kidney Management in HFmrEF/HFpEF

FINEARTS-HF Trial (2025) - Multicenter RCT

Key Findings

  • Finerenone reduced the risk of cardiovascular death and total heart failure events.
  • Hyperkalemia was more frequent (9.7% vs 4.2%), but rarely led to treatment discontinuation.
  • Benefits were consistent across baseline kidney function and potassium levels.

📋 Practice Implication: Finerenone should be considered a key therapeutic option for HFpEF, with monitoring of potassium and renal function.

2. GLP-1 Receptor Agonists in Obesity-Related HFpEF

STEP-HFpEF Program (2025/2026) - Multi-study RCT Analysis

Key Findings

  • Semaglutide 2.4 mg significantly improved KCCQ-CSS scores (symptom burden) and 6-minute walk distance.
  • Weight loss was strongly correlated with improvements in heart failure symptoms and physical limitations.
  • Benefits were consistent across the age spectrum and independent of baseline frailty status.

📋 Practice Implication: GLP-1 agonists represent a disease-modifying therapy for the obesity-HFpEF phenotype beyond simple weight loss.

3. CCS/CHFS 2025 Guideline Update for HF >40% LVEF

Canadian Cardiovascular Society (2025) - Practice Guideline

Key Findings

  • Strong recommendation for SGLT2 inhibitors (Dapagliflozin/Empagliflozin) as first-line therapy for LVEF >40%.
  • Conditional recommendation for MRAs (Spironolactone/Finerenone) and ARNI (Sacubitril/Valsartan) in selected patients.
  • Emphasis on treating comorbidities (obesity, hypertension, AF) as core HF management.

📋 Practice Implication: Clinicians should prioritize SGLT2i as the foundational therapy for all HF patients regardless of ejection fraction.

4. Optimal Quadruple Therapy Combinations in HFrEF

Frontiers in Endocrinology (2025/2026) - Network Meta-Analysis

Key Findings

  • Sotagliflozin-based quadruple therapy ranked highest for preventing CV death and hospitalizations.
  • Dapagliflozin and ARNI showed comparable, significant reductions in all-cause mortality.
  • SGLT2 inhibitors provided consistent renal protection across regimens.

📋 Practice Implication: Rapid initiation of 'four pillar' quadruple therapy remains the gold standard, with SGLT2i choice potentially tailored to renal risk.

📊 Additional Notable Studies

Notable mentions: DANISH Trial extended follow-up showed ICDs benefit non-ischemic HFrEF patients with lower frailty; VICTOR Trial confirmed Vericiguat's benefit in reducing total HF events in compensated outpatients.

💡 Summary

Recent guidelines and trials emphasize the expanding role of GLP-1 agonists (semaglutide, tirzepatide) and MRAs (finerenone) in HFpEF, alongside the consolidated 'four pillars' (including SGLT2i and ARNI) for HFrEF management.

Generated from 100 PubMed abstracts · RCTs and Meta-analyses only

Next topic: Hypertension Management in the Elderly (SND-Target Guidelines)